Rare Disorders: Ipsen initiates partial clinical hold in the pediatric population for palovarotene studies investigating the chronic treatment of fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO)

https://www.ipsen.com/press-releases/ipsen-initiates-partial-clinical-hold-for-palovarotene-ind120181-and-ind135403-studies/